View/ Open
Shang_Cancer_Management_and_Research.pdf (178.5Kb)
Download
Publication date
2018-10-15Rights
© 2018 Zhang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.Peer-Reviewed
YesOpen Access status
openAccess
Metadata
Show full item recordAbstract
In recent years, the reports on using nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer prevention and treatment have been on the rise. In 2017, the US Preventive Services Working Group issued primary prevention guidelines on the use of NSAIDs, especially aspirin, for cardiovascular disease and colorectal cancer, and formally established the role and status of aspirin in cancer prevention. However, the mechanism of NSAIDs on preventing cancer is still not clear. In this paper, the progress of the application of NSAIDs, especially aspirin, in the prevention and treatment of tumors in recent years is summarized, and new ideas and directions for the follow-up study are also discussed.Version
Published versionCitation
Zhang Z, Chen F and Shang L (2018) Advances in antitumor effects of NSAIDs. Cancer Management and Research. 10: 4631-4640.Link to Version of Record
https://doi.org/10.2147/CMAR.S175212Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.2147/CMAR.S175212